A Spine-Surgery Robot Turned This Entrepreneur Into A Billionaire. But How Well Does His Robot Work?

When David C. Paul traveled to Phoenix in 2013, he saw the future of spinal surgery: a robot prototype called the Excelsius GPS. Nicholas Theodore, one of the robot’s inventors, remembers Paul being immediately impressed. “This is going to change everything,” Paul said, according to Theodore. A few months later, Paul bought Theodore’s company, Excelsius Surgical—and the robot with it—for an undisclosed sum.

Paul, 51, couldn’t have hoped for more from the purchase. Since 2014, shares of Globus Medical, Paul’s publicly traded device manufacturer, have more than doubled. Just since the robot received FDA clearance in August 2017, the stock has climbed 65%. Paul owns nearly a quarter of the firm. That stake and recent stock sales add up to a $1.3 billion fortune. Paul, who stepped down as CEO and moved to the executive chairman role last year while recovering from what the company referred to in a press release as a “health condition,” still maintains tight control over the business—owning 76% of the company’s voting shares, according to the latest proxy. (Paul, through a Globus spokesman, declined to be interviewed.)

The Excelsius GPS is one of only two spine-surgery robots on the market, and Globus, which is based in Audubon, Pennsylvania, says it can help surgeons perform spinal fusions by placing screws more quickly and accurately. At this point, though, there’s little large-scale published data to show that Excelsius, which costs more than $1 million per unit, is any better than a surgeon putting in the screws on his or her own; Johns Hopkins University researchers are preparing studies on accuracy and patient outcomes.

There’s a scramble right now to add robots to operating rooms, and money is flowing in that direction. Two months ago medical device maker Medtronic announced its plan to acquire Mazor Robotics, the publicly traded Israeli creator of the other spine-surgery robot on the market, in a deal valuing the company at about $1.6 billion, a 16% premium to the closing share price the day before the acquisition was announced. “I think everyone’s very excited about robots,” says Dr. Jeffrey Wang, orthopedic surgeon and president of the North American Spine Society. “It sounds kind of sexy, and I think people realize there is a lot of potential there.”

By Michela Tindera | Forbes

Image Credit: Globus Medical


About Peter Coffaro 658 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the orthopedic industry. Recognized by MedReps.com and the World Journal of Orthopedics as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager, Distributor and Vice President. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy and Stryker. He is also the founder of OrthoFeed: a popular blog that covers digital orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing and professional education. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.